- Pliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™
- Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Events
- Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
- Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
- Pliant Therapeutics to Participate in Upcoming Investor Conferences
- Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
- Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
More ▼
Key statistics
As of last trade, Pliant Therapeutics Inc (PLRX:NSQ) traded at 13.38, 19.36% above the 52 week low of 11.21 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.95 |
---|---|
High | 14.00 |
Low | 13.33 |
Bid | 13.35 |
Offer | 13.38 |
Previous close | 13.81 |
Average volume | 364.55k |
---|---|
Shares outstanding | 60.32m |
Free float | 56.45m |
P/E (TTM) | -- |
Market cap | 833.00m USD |
EPS (TTM) | -2.86 USD |
Data delayed at least 15 minutes, as of May 10 2024 18:17 BST.
More ▼